Tirzepatide is designed for long-term use as part of a comprehensive weight management program
Etrasimod, a more selective S1PR1/4/5 modulator requiring no dose escalation and administered at 2mg once daily from initiation, achieved FDA approval in 2023 and EMA approval in 2024 based on ELEVATE UC 52 and UC 12 demonstrating 27% clinical remission at week 12 and 32% at week 52 versus 7% placebo at both timepoints, with rapid symptomatic improvement by day 2 and maintained efficacy in biologic/JAK-experienced patients (17-21% remission) and notably in isolated proctitis (43% remission at week 12) ( This section reviews investigational anti-trafficking and adhesion molecules currently in Phase II and III clinical development for moderate to severe UC
The Gold Thyroid Blood Test is a popular choice because it monitors your thyroid hormones (TSH, Free T4, Free T3) along with key nutrients (Vitamin D, B12, Ferritin) that support metabolism
Much simpler than topical applications
Editor's note: This story was initially published on March 20 and was updated on March 29 after the British Columbia Ministry of Health said it would ban pharmacies in the province from filling Ozempic prescriptions for non-Canadian residents.
7.5 Strengthening global regulatory and public health initiatives International collaboration remains essential for standardizing exposure limits, improving biomonitoring frameworks, and enhancing public awareness of EED-related reproductive health risks
.png)